Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 08 2018
accepted: 07 01 2019
pubmed: 15 1 2019
medline: 21 3 2020
entrez: 15 1 2019
Statut: ppublish

Résumé

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients with multiple myeloma, as it provides a graft-versus-myeloma effect alongside a myeloma-free graft. Although reduced-intensity conditioning regimens decrease nonrelapse mortality (NRM), there is a paucity of data with regard to the ideal conditioning regimen in myeloma. We conducted a retrospective comparison of 3 different preparative regimens used for allo-HCT for multiple myeloma at our institution in recent clinical trials: busulfan/fludarabine (BuFlu), fludarabine/melphalan 100 mg/m

Identifiants

pubmed: 30639822
pii: S1083-8791(19)30024-2
doi: 10.1016/j.bbmt.2019.01.009
pmc: PMC7053532
mid: NIHMS1066114
pii:
doi:

Substances chimiques

Butyrophenones 0
Vidarabine FA2DM6879K
Busulfan G1LN9045DK
metylperon J8WA3K39B7
fludarabine P2K93U8740

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1039-1044

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009666
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Références

Blood. 2006 May 1;107(9):3474-80
pubmed: 16397129
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
Cancer. 2013 Dec 1;119(23):4119-28
pubmed: 24005889
Blood. 2015 Nov 12;126(20):2284-90
pubmed: 26384354
Br J Haematol. 2003 Dec;123(5):886-95
pubmed: 14632780
N Engl J Med. 2016 Apr 28;374(17):1621-34
pubmed: 27119237
Am J Hematol. 2012 Mar;87(3):272-6
pubmed: 22231283
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Blood. 2005 Jun 1;105(11):4532-9
pubmed: 15731182
Blood. 2011 Sep 1;118(9):2413-9
pubmed: 21690556
Br J Haematol. 2001 Apr;113(1):209-16
pubmed: 11360893
Blood. 1996 Feb 1;87(3):1196-8
pubmed: 8562947
Biol Blood Marrow Transplant. 2016 Jan;22(1):54-60
pubmed: 26211984
N Engl J Med. 2014 Sep 4;371(10):895-905
pubmed: 25184862
Blood. 2007 Apr 15;109(8):3588-94
pubmed: 17158231
Blood. 1996 Dec 15;88(12):4711-8
pubmed: 8977265
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Bone Marrow Transplant. 2014 Mar;49(3):416-21
pubmed: 24270389
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
Leukemia. 2008 Jun;22(6):1250-5
pubmed: 18418408
Leuk Lymphoma. 2012 Aug;53(8):1525-9
pubmed: 22242817
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):349-357.e2
pubmed: 25958193
Haematologica. 2011 Oct;96(10):1504-11
pubmed: 21685472
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Biol Blood Marrow Transplant. 2014 Aug;20(8):1183-9
pubmed: 24769014
J Clin Oncol. 2006 Feb 20;24(6):929-36
pubmed: 16432076
Lancet Oncol. 2011 Dec;12(13):1195-203
pubmed: 21962393
Lancet Oncol. 2015 Dec;16(16):1617-29
pubmed: 26596670
Blood. 2011 Aug 18;118(7):1979-88
pubmed: 21690560
Biol Blood Marrow Transplant. 2018 Jul;24(7):1399-1405
pubmed: 29684563
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
J Clin Oncol. 1999 Jan;17(1):208-15
pubmed: 10458235
Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8
pubmed: 23872222
Blood. 2004 Jun 1;103(11):4362-4
pubmed: 14976044

Auteurs

Hossein Maymani (H)

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Paul Lin (P)

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Rima M Saliba (RM)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Uday Popat (U)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Qaiser Bashir (Q)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Nina Shah (N)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Krina Patel (K)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Simrit Parmar (S)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Partow Kebriaei (P)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Chitra Hosing (C)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Stefan Ciurea (S)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Borje Andersson (B)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Elizabeth Shpall (E)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Richard Champlin (R)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Samer A Srour (SA)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Muzaffar H Qazilbash (MH)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: mqazilba@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH